World Journal of Surgical Oncology最新文献

{"title":"Omission of completion axillary dissection in clinically node-negative breast cancer with 1-2 metastatic sentinel lymph nodes.","authors":"Weiqiang Qiao, Xiao Guo, Peng Li, Qipeng Liu, Miao Deng","doi":"10.1186/s12957-026-04401-8","DOIUrl":"https://doi.org/10.1186/s12957-026-04401-8","url":null,"abstract":"<p><strong>Background: </strong>The SENOMAC trial demonstrated that omitting completion axillary lymph node dissection (ALND) is safe in patients with clinically node-negative (cN0) T1, T2, or T3 breast cancer with 1-2 sentinel-node macrometastases. However, its applicability to populations with higher mastectomy rates, such as in China, remains unclear. This study evaluated the safety and efficacy of omitting completion ALND in cN0 T1-T2 breast cancer patients who underwent sentinel lymph node biopsy (SLNB) with 1-2 SLN macrometastases in a Chinese cohort.</p><p><strong>Methods: </strong>This single-center retrospective study included 202 patients diagnosed between January 1, 2017, and December 31, 2023, who underwent SLNB at our institute. Patients were divided into SLNB-only (n = 93) and completion ALND (n = 109) groups. Baseline characteristics were compared using chi-square or t-tests; survival outcomes and complications via Kaplan-Meier analysis, log-rank tests, and Cox proportional-hazards regression.</p><p><strong>Results: </strong>Median follow-up was 58 months (range = 3-103). No significant differences were found in 5-year recurrence-free survival (95.7%, vs. 94.5%, P = 0.96) and overall survival (OS) (97.8%, vs. 97.2%, P = 0.84) between the SLNB-only and completion ALND groups. The incidence of lymphedema, assessed by combined subjective and objective criteria, was significantly lower in the SLNB-only group than in the completion ALND group (4.3%, vs. 12.8%, P = 0.03). Hormone-receptor-positive status was an independent prognostic factor for OS (hazard ratio = 0.04, 95% confidence interval 0.004-0.46, P = 0.01].</p><p><strong>Conclusion: </strong>In this retrospective cohort, omission of completion ALND was not associated with a statistically significant difference in 5-year RFS or OS compared with completion ALND, while lymphedema incidence was significantly lower. These findings suggest that omitting ALND may be feasible in selected patients with cN0 T1-T2 breast cancer and 1-2 SLN macrometastases. However, given the study's limitations, future larger, prospective, randomized, and multicenter studies are needed to confirm these findings.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147857337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional outcomes and survival analysis of modular endoprostheses following resection of upper extremity tumors: a retrospective clinical study.","authors":"Özer Öztürk, Samed Çatal, Mert Gündoğdu, Osman Mert Topkar, Bülent Erol","doi":"10.1186/s12957-026-04335-1","DOIUrl":"https://doi.org/10.1186/s12957-026-04335-1","url":null,"abstract":"<p><strong>Background: </strong>Advances in chemotherapy and radiotherapy have significantly improved patient survival. Furthermore, advancements in implant technology have enabled the successful application of endoprostheses in many cases in which reconstruction via biological methods is not feasible. This study aimed to assess implant survival, overall patient survival, and functional outcomes in patients who underwent upper extremity tumor resection.</p><p><strong>Methods: </strong>This study had a retrospective design. Patients who underwent resection and endoprosthetic reconstruction between 2011 and 2020 were evaluated. After applying the inclusion and exclusion criteria, 90 patients were included in this study. Factors potentially influencing endoprosthesis and patient survival were identified and analyzed. Functional assessment was performed by measuring the Musculoskeletal Tumor Society (MSTS) scores of patients during outpatient clinic follow-ups.</p><p><strong>Results: </strong>The mean follow-up period was 36 ± 19.4 months. Implant failure occurred in eight of the 90 patients, resulting in a total endoprosthesis survival rate of 91.1%. Among the eight patients with implant failure, aseptic loosening was observed in two, infection in four, and tumor progression in two cases. During the study period, 37 patients died, resulting in an overall patient survival rate of 58.8%. The mean MSTS score for functional assessment was 22.1 ± 2.564. Studies in the literature suggest that the use of synthetic meshes contributes to improved functional outcomes. The mean MSTS score was 23.2 ± 2.370 for patients with synthetic mesh, compared to 21.5 ± 2.575 for those without, a statistically significant difference (P = 0.005). The overall patient survival rate was 58.8%. Two of the 90 patients underwent amputation, and the limb survival rate was 97.7%. The notably higher implant survival rate compared to patient survival and high limb survival rates indicate favorable outcomes consistent with the intended use of endoprosthetic reconstructions.</p><p><strong>Conclusion: </strong>Modular endoprostheses are a preferred successful reconstruction method following upper extremity tumor resections owing to their long-term survival and low complication rates.</p><p><strong>Level of evidence: </strong>Level IV.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147857318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Germline HLA-I genotypes predict pathologic response and survival outcomes in esophageal cancer patients undergoing neoadjuvant immunochemotherapy: a retrospective cohort study.","authors":"Willis Wasonga Omindo, Qi Wang, Siyou Deng, Ruijie Zhang, Wei Sun, Li Zhang, Ni Zhang","doi":"10.1186/s12957-026-04374-8","DOIUrl":"https://doi.org/10.1186/s12957-026-04374-8","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant immunochemotherapy (nICT) has reshaped the treatment paradigm for locally advanced esophageal cancer (EC), but patient responses remain highly heterogeneous. Reliable biomarkers to predict therapeutic benefit are urgently needed. Class I human leukocyte antigen (HLA-I) molecules are essential for anti-tumor immunity, presenting neoantigens to cytotoxic T lymphocytes.This study investigated the relationship between germline HLA-I genotypes and treatment response in patients with esophageal cancer receiving nICT.</p><p><strong>Methods: </strong>We retrospectively analyzed 30 Chinese EC patients who underwent surgery following nICT. High-resolution sequencing was used to determine germline HLA-I genotypes. Associations between specific HLA alleles and both short-term pathologic response and long-term survival outcomes, including pathologic complete response (pCR) and event-free survival (EFS) were evaluated.</p><p><strong>Results: </strong>HLA-A*11:01 carriers exhibited significantly prolonged EFS compared with non-carriers (P = 0.015). In contrast, the HLA-A*24:02 allele was more frequent in non-pCR patients (50.0% vs. 12.5%, P = 0.064), and shorter EFS was observed among carriers (median 16.0 vs. 38.8 months, P = 0.063), although these differences did not reach statistical significance. HLA-I homozygosity was more common among patients who achieved pCR (75.0% vs. 27.3%, P = 0.034).</p><p><strong>Conclusion: </strong>In this small retrospective cohort, germline HLA-I genotypes were associated with differences in pathologic response and event-free survival following nICT. These findings should be interpreted as exploratory and hypothesis-generating, requiring validation in larger prospective studies before clinical translation.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management and prognostic outcomes of gastrointestinal stromal tumors in Sub-Saharan Africa: the central role of surgery in resource-limited settings: a systematic review and meta-analysis (2014-2024).","authors":"Freddy Houéhanou Rodrigue Gnangnon, Christian Godjo, Pervenche Fotso, René Ayaovi Gayito Adagba, Dansou Gaspard Gbessi, Francis Moïse Dossou","doi":"10.1186/s12957-026-04347-x","DOIUrl":"https://doi.org/10.1186/s12957-026-04347-x","url":null,"abstract":"<p><strong>Background: </strong>Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract. However, data from Sub-Saharan Africa (SSA) remain fragmented, and no prior systematic review has synthesized regional diagnostic and treatment practices.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis following PRISMA 2020 guidelines (PROSPERO: CRD42024575650). PubMed, Embase, Scopus, Google Scholar, and African Journals Online were searched for studies published between January 2014 and June 2024. Eligible population-, community-, and hospital-based studies reporting on GIST management or prognosis in SSA were included. Study quality was assessed using Joanna Briggs Institute tools. Random-effects models (REML with Hartung-Knapp adjustment) were used to estimate pooled outcomes.</p><p><strong>Results: </strong>Twenty-one studies comprising 410 patients met inclusion criteria. The median age ranged from 52 to 56 years, and the male-to-female ratio was approximately 1.3:1. The stomach was the most frequent tumor site (64.1%), followed by the small intestine (14.6%). Most patients were symptomatic at diagnosis, with abdominal pain (50.4%) and abdominal mass (47.3%) being the predominant complaints. Computed tomography was the primary imaging modality (99.5%). Surgery was performed in 70% of patients, with R0 resection achieved in 68.2%. Imatinib was used as neoadjuvant (n = 58), adjuvant (n = 64), or palliative therapy (n = 75). Among 199 evaluable patients, the pooled disease-control rate was 77.3% (CR: 32.5%; PR: 27.9%; SD: 7.9%), while progressive disease occurred in 18.9%. The pooled median overall survival was 44.0 months. Postoperative mortality was 0.7%, and overall mortality during follow-up was 9.8%.</p><p><strong>Conclusion: </strong>This review provides the first comprehensive synthesis of GIST management in Sub-Saharan Africa. Despite limited diagnostic infrastructure and late presentations, therapeutic outcomes particularly disease control with imatinib and low postoperative mortality appear numerically comparable in selected settings where treatment is accessible, although structural and methodological disparities preclude direct equivalence. Strengthening early detection, expanding immunohistochemistry and molecular testing, and improving access to tyrosine kinase inhibitors remain critical for improving survival in the region.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative outcomes in patients with gastric cancer undergoing prehabilitation in a high-complexity referral centre.","authors":"Oscar Julian Suescun Fajardo, Sameer Torres Gaviria, Mauricio Chona Chona, Lina López Basto, Jorge Medina Parra, Ricardo Merchán Chaverra","doi":"10.1186/s12957-026-04310-w","DOIUrl":"https://doi.org/10.1186/s12957-026-04310-w","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer remains one of the most frequent oncological diseases, often associated with a high rate of postoperative complications. Prehabilitation has shown benefits in other surgical settings, although its role in gastric cancer patients remains under investigation.</p><p><strong>Objective: </strong>To describe the postoperative outcomes of patients with gastric cancer who underwent a prehabilitation programme in a high-complexity referral centre in Bogotá, Colombia.</p><p><strong>Methods: </strong>A descriptive observational retrospective cohort study was conducted at Clínica Universitaria Colombia between January 2021 and December 2023. Patients aged 18-80 years with a confirmed diagnosis of gastric cancer who underwent surgical treatment were included.</p><p><strong>Results: </strong>A total of 140 patients with gastric cancer received prehabilitation. The mean age was 60.9 years, and 60% were male. Postoperative complications occurred in 23.6% of patients, with surgical site infection being the most frequent (17.1%). Admission to the intensive care unit was required in 7.1%, and overall mortality was 4.3%. In bivariate analysis, malnourished patients presented higher rates of total complications, surgical site infection, and ICU admission.</p><p><strong>Conclusions: </strong>Malnutrition is consistently associated with worse postoperative outcomes. Therefore, prehabilitation plays a crucial role in improving nutritional and functional parameters that directly influence the recovery and prognosis of patients with gastric cancer.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is surgery necessary for mismatch repair-deficient/microsatellite instability-high colorectal cancer patients with a clinical complete response after neoadjuvant immunotherapy? A retrospective cohort study with literature context.","authors":"Hongqun Zuo, Jian Huang, Shengquan Peng, Jie Wei, Yinxiang Luo, Shimeng Qin, Xiaojun Zou, Ju Rong, Yuan Lin, Hao Lai, Xianwei Mo","doi":"10.1186/s12957-026-04382-8","DOIUrl":"https://doi.org/10.1186/s12957-026-04382-8","url":null,"abstract":"<p><strong>Background: </strong>The purpose of this study was to retrospectively compare the prognostic outcomes of patients with colorectal cancer (CRC) who achieved a clinical complete response (CCR) after neoadjuvant immunotherapy (NI) and those who achieved a CCR after surgery. A literature review of publications was conducted in the PubMed database.</p><p><strong>Materials and methods: </strong>This study included 70 patients who were diagnosed with mismatch repair deficiency/microsatellite instability high (dMMR/MSI-H) colorectal cancer and who were treated with NI between 2018 and 2024. CCR patients were grouped into the \"watch and wait\" (W&W) method group or the radical surgery group. Afterwards, the oncological and clinical outcomes of patients who achieved a clinical complete response (CCR) were compared to those of patients who were classified as tumour free. We also conducted a literature review of publications in the PubMed database of clinical studies that compared clinical outcomes between W&W and surgery for CCR dMMR/MSI-H patients.</p><p><strong>Results: </strong>Among the 70 NI-treated dMMR/MSI-H CRC patients, 44 (62.86%) achieved a CCR. Of these, 25 patients were managed with a watch-and-wait (W&W) strategy, while 19 underwent curative-intent surgery. In the surgery group, 16 patients (84.21%) achieved a pathological complete response (pCR). During follow-up, 2 patients (10.53%) in the surgery group developed recurrence, and both subsequently died, while the remaining 17 patients were alive at the last follow-up. No statistically significant differences were observed between the W&W and surgery groups in terms of recurrence or survival outcomes. A literature review including nine studies further demonstrated comparable oncological outcomes between W&W and surgical management in patients who achieved a CCR.</p><p><strong>Conclusion: </strong>Patients in the W&W group presented similar oncological outcomes to those who underwent surgery. Surgery may not be necessary for patients with dMMR/MSI-H colorectal cancer who achieve a clinical complete response after neoadjuvant immunotherapy. However, large sample sizes and multicentre investigations are needed to validate these findings.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The predictive value of multidimensional frailty instruments for postoperative adverse outcomes in cancer patients: a systematic review and meta-analysis.","authors":"Yue Chen, Shulin Song, Ziyan Wang, Yinning Guo, Zhongmin Fu, Ting Xu, Yi Chen, Zhichao Jiang, Lingyu Ding, Qin Xu","doi":"10.1186/s12957-026-04365-9","DOIUrl":"https://doi.org/10.1186/s12957-026-04365-9","url":null,"abstract":"<p><strong>Purpose: </strong>To systematically review the predictive performance of Tilburg Frailty Indicator (TFI), Groningen Frailty Indicator (GFI), and Edmonton Frailty Scale (EFS) for adverse outcomes including postoperative complications, unplanned readmission, 30-day mortality, prolonged length of stay among cancer patients.</p><p><strong>Materials and methods: </strong>A comprehensive search was conducted across English and Chinese databases until October 2, 2025. Risk of bias was assessed using Quality Assessment of Diagnostic Accuracy Studies 2 tool. Predictive performance was evaluated by pooling sensitivity, specificity, and summary receiver operating characteristic curves.</p><p><strong>Results: </strong>There were 21 studies (4,435 individuals) that were included for the meta-analysis. TFI demonstrated pooled sensitivities of 0.64 (for postoperative complications), 0.77 (for unplanned readmission), and 0.50 (for prolonged hospital stay), with corresponding specificities of 0.67, 0.54, and 0.64 respectively. The areas under the curve (AUC) were 0.70, 0.71, and 0.60. GFI demonstrated sensitivities of 0.59, 0.65, and 0.55 for complications, 30-day mortality, and functional decline, with specificity of 0.73, 0.63, and 0.77, and the AUC of 0.71, 0.68, and 0.74. EFS had sensitivity 0.39, specificity 0.87, and AUC 0.57 for complications. Subgroup analysis revealed that TFI had reasonable predictive value for adverse outcomes with sensitivity 0.61-0.81 and specificity 0.60-0.68 among most gynecological and gastrointestinal cancer subgroups. In most subgroups, GFI showed higher specificity (0.64-0.84) relative to sensitivity (0.43-0.68).</p><p><strong>Conclusion: </strong>TFI and GFI demonstrated moderate predictive validity for adverse outcomes, whereas EFS exhibited poor predictive performance. These findings highlight the necessity for caution interpretation of frailty assessments in clinical practice and underscore the importance of further validating these tools within diverse oncological contexts.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nomogram predicting outcomes in HCC patients treated with TACE-HAIC, TKIs, and PD-1 inhibitors.","authors":"Jie Chen, Yangdingxin Li, Yong Wang, Yan Li, Junbiao Li, Yuxiang Yuan, Chaoqian Wang, Wei Xu","doi":"10.1186/s12957-026-04342-2","DOIUrl":"https://doi.org/10.1186/s12957-026-04342-2","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to develop and validate a prognostic nomogram to predict overall survival (OS) in patients with Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) undergoing multimodal therapy, combining transarterial chemoembolization, hepatic arterial infusion chemotherapy, tyrosine kinase inhibitors, and programmed death-1 inhibitors.</p><p><strong>Methods: </strong>A retrospective analysis included 193 patients with BCLC stage C HCC treated at Xuzhou Medical University Affiliated Hospital between February 2021 and February 2024. Patients were randomly divided into a training cohort (n = 135) and a validation cohort (n = 58). Independent prognostic factors were identified via Cox regression analysis. A nomogram was developed and evaluated using the concordance index (C-index), time-dependent receiver operating characteristic curves, calibration plots, and decision curve analysis. Risk stratification was performed using X-tile software.</p><p><strong>Results: </strong>The median OS was 402 days. Multivariate analysis identified ALBI grade (HR [Hazard Ratio] = 10.09-19.63), maximum tumor diameter ≥ 5 cm (HR = 2.69), multiple tumors (HR = 2.59), and vascular invasion (HR = 2.74) as independent predictors of OS. The nomogram demonstrated strong discriminatory performance, with C-indices of 0.788 in the training cohort and 0.805 in the validation cohort. The time-dependent AUCs for 1-year and 1.5-year OS were 0.879 and 0.887 in the training cohort, and 0.923 and 0.832 in the validation cohort, respectively. Calibration curves showed excellent agreement between predicted and observed outcomes. Decision curve analysis supported the clinical utility of the model. Risk stratification based on the nomogram revealed significant survival differences between the low- and high-risk groups (median OS: 566 vs. 454 days; P < 0.001).</p><p><strong>Conclusions: </strong>This novel nomogram, integrating locoregional and systemic therapies, offers an individualized tool for prognostication in patients with BCLC stage C HCC, potentially guiding therapeutic decision-making and patient counseling.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The FGD5-AS1/miR-142-5p/CDK5 axis promotes ESCC progression by regulating mitochondrial fission and mitophagy: insights from integrative bioinformatics and experimental analyses.","authors":"Min Hou, Shan Chen, Huadong Yang, Qingmei Huang, Hongmei Zhan, Yan Gui","doi":"10.1186/s12957-026-04338-y","DOIUrl":"https://doi.org/10.1186/s12957-026-04338-y","url":null,"abstract":"","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of survival outcomes between local excision and radical resection in patients with rectal mucosal melanoma.","authors":"Jingyu Zou, Heyuan Zhu, Yongqin Tang, Ying Huang, Pan Chi, Xiaojie Wang","doi":"10.1186/s12957-026-04257-y","DOIUrl":"https://doi.org/10.1186/s12957-026-04257-y","url":null,"abstract":"","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}